The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

Shares of Gilead Sciences, Inc. (GILD) tumbled 2.2% on Aug. 21, after pharmacy benefit manager CVS Health (CVS) decided not ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.

Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

Advocates for HIV prevention are calling a newly approved injectable medication a major step in eliminating the spread of the ...

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

Gilead Sciences has secured approval from the United States health authorities for its new HIV prevention injection, Yeztugo, but concerns are growing over its steep price tag.